A Prospective Clinical Study to Evaluate the Efficacy and Safety of a Probiotic Combination of Bacillus clausii 088AE, Bacillus coagulans LBSC and Bacillus subtilis PLSSC as Immunomodulators in Acute Allergic Rhinitis

Published: 21 October 2021| Version 1 | DOI: 10.17632/dxx7czctmx.1


The proposed study is planned on three proprietary spore forming Bacillus probiotics, viz., B. subtilis, B. coagulans and B. clausii for their ability to induce immune system by modulating a series of inflammatory markers and immune cells in allergic rhinitis. The effect of B. clausii, B. coagulans and B. subtilis is well established for immunomodulatory activity in human studies and proven to be safe (Gupta and Maity, 2021). The present study highlights the efficacy and safety of a combination of B. clausii 088AE, B. coagulans LBSC and B. subtilis PLSSC and demonstrates their immunomodulatory effect in acute allergic rhinitis.



Advanced Enzyme Technologies Ltd


Clinical Trial, Immunotherapy, Probiotics, Allergic Rhinitis, Clinical Trial Results